prikaz prve stranice dokumenta Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
  Preuzmi
PDF 642.34 KB
Znanstveni rad - Izvorni znanstveni rad
Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
Antibodies, 12 (2023), 2; 37. https://doi.org/10.3390/antib12020037
Premužić, Vedran; Stevanović, Ranko; Vilibić-Čavlek, Tatjana; Sirovica, Maja; Stalman, Sara; Bogdanić, Maja; Žilić, Denis; Nakić, Dario; Santini Dušević, Danijela; Vojković, Marina; Barbić, Jerko; Durlen, Ivan; Grđan, Željka; Pavlović, Draško; Kudumija, Boris; Sefer, Siniša; Griparić, Davor; Rogić, Dunja; Bubaš, Marija; Capak, Krunoslav; Jelaković, Bojan Više autora...

Citirajte ovaj rad

Premužić, V., Stevanović, R., Vilibić Čavlek, T., Sirovica, M., Stalman, S., Bogdanić, M. ... Jelaković, B. (2023). Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity. Antibodies, 12. (2). doi: 10.3390/antib12020037

Premužić, Vedran, et al. "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity." Antibodies, vol. 12, br. 2, 2023. https://doi.org/10.3390/antib12020037

Premužić, Vedran, Ranko Stevanović, Tatjana Vilibić Čavlek, Maja Sirovica, Sara Stalman, Maja Bogdanić, Denis Žilić, et al. "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity." Antibodies 12, br. 2 (2023). https://doi.org/10.3390/antib12020037

Premužić, V., et al. (2023) 'Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity', Antibodies, 12(2). doi: 10.3390/antib12020037

Premužić V, Stevanović R, Vilibić Čavlek T, Sirovica M, Stalman S, Bogdanić M, i sur.. Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity. Antibodies [Internet]. 24.05.2023. [pristupljeno 08.11.2024.];12(2). doi: 10.3390/antib12020037

V. Premužić, et al., "Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity", Antibodies, vol. 12, br. 2, Svibanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:513281. [Citirano: 08.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:513281
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity
AutorVedran Premužić
AutorRanko Stevanović
AutorTatjana Vilibić-Čavlek
AutorMaja Sirovica
AutorSara Stalman
AutorMaja Bogdanić
AutorDenis Žilić
AutorDario Nakić
AutorDanijela Santini Dušević
AutorMarina Vojković
AutorJerko Barbić
AutorIvan Durlen
AutorŽeljka Grđan
AutorDraško Pavlović
AutorBoris Kudumija
AutorSiniša Sefer
AutorDavor Griparić
AutorDunja Rogić
AutorMarija Bubaš
AutorKrunoslav Capak
AutorBojan Jelaković
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MEDICINSKU MIKROBIOLOGIJU I PARAZITOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Medicinska mikrobiologija
Sažetak (engleski)
Background: The effectiveness of the COVID-19 vaccine may differ in hemodialysis patients. The aim of this prospective multicenter study was to determine the degree of serological response to the SARS-CoV-2 vaccine in the population of dialysis patients and its association with later SARS-CoV-2 infections. Methods: A blood sample was taken for the determination of COVID-19 serological status (IgG antibodies) in 706 dialysis patients 16 weeks after vaccination with the second dose (Pfizer-BioNTech). Results: Only 314 (44.5%) hemodialyzed patients had a satisfactory response to the COVID-19 vaccine. Eighty-two patients (11.6%) had a borderline response, while 310 patients (43.9%) had an unsatisfactory (negative) post-vaccinal antibody titer. A longer dialysis vintage had an increased odds ratio (OR) of 1.01 for the occurrence of COVID-19 positivity after vaccination. In the group of subsequently positive patients, 28 patients (13.6%) died from complications of COVID-19. We have found differences in mean survival time between patients with and without appropriate responses to vaccination in favor of patients with a satisfactory serological response. Conclusions: The results showed that the dialysis population will not have the same serological response to the vaccine as the general population. The majority of dialysis patients did not develop a severe clinical picture or die at the time of positivity for COVID-19.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAntibodies
Brojčani podacivol. 12, br. 2, 37
e-ISSN2073-4468
DOIhttps://doi.org/10.3390/antib12020037
URN:NBNurn:nbn:hr:105:513281
Datum objave publikacije2023-05-24
URL dokumentahttps://www.mdpi.com/2073-4468/12/2/37
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-09-25 08:34:36